Israel based Scentech-Medical announced it had received approval from the Shamir Medical Center Review Board for a new clinical trial to demonstrate its ability to monitor the antibody levels and type of antibodies developed by the population of subjects getting vaccinated for the SARS-CoV-2 coronavirus.
Scentech, which is merging with NextGen Biomed Ltd, reports that using the test developed for the analysis and quantification of volatile compounds in breath can detect coronavirus patients, active, symptomatic, and asymptomatic carriers.
Read More
